GeoVax Labs Files 8-K on Financials and Operations

TL;DR

GeoVax Labs dropped an 8-K on Nov 12th covering financials & operations. Check it out.

AI Summary

GeoVax Labs, Inc. filed an 8-K on November 13, 2024, reporting on its financial condition and other events. The filing includes information on results of operations and financial statements, with the earliest event reported being November 12, 2024.

Why It Matters

This 8-K filing provides an update on GeoVax Labs' financial condition and operational events, which is crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant news, but this specific filing appears to be a routine update on financial condition and operations, not a major event like an acquisition or bankruptcy.

Key Players & Entities

• GeoVax Labs, Inc. (company) — Registrant
• November 12, 2024 (date) — Earliest event reported
• November 13, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M

Filing Documents

• govx20241113_8k.htm (8-K) — 28KB
• ex_747310.htm (EX-99.1) — 94KB
• logosm.jpg (GRAPHIC) — 12KB
• 0001437749-24-034910.txt ( ) — 300KB
• govx-20241112.xsd (EX-101.SCH) — 4KB
• govx-20241112_def.xml (EX-101.DEF) — 14KB
• govx-20241112_lab.xml (EX-101.LAB) — 18KB
• govx-20241112_pre.xml (EX-101.PRE) — 14KB
• govx20241113_8k_htm.xml (XML) — 5KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the "Filings") contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by the Company's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company's industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 12, 2024, GeoVax Labs, Inc. (the "Company") issued a press release reporting its results of operations for the quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01 Other Events

Item 8.01 Other Events. The Company re-convened a Special Meeting of Stockholders (the "Special Meeting") on November 12, 2024 (originally convened on September 17, 2024) and adjourned the Special Meeting without any business being conducted due to lack of the required quorum. The Company has determined to keep the polls open and reconvene the Special Meeting on December 18, 2024 at 8:30 a.m. Eastern Time to provide its stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission on August 1, 2024. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 30.4% of the shares of the Company's common stock outstanding and entitled to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 13, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR